Published in Health and Medicine Week, January 24th, 2005
"The FDA's decision is another milestone demonstrating Affymetrix' commitment to clinical diagnostic products," said Stephen P.A. Fodor, PhD, chairman and CEO of Affymetrix.
"We can now offer our diagnostic partners an FDA-cleared system to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.